Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation

The majority of patients with systemic mast cell disease express the imatinib-resistant Asp816Val (D816V) mutation in the KIT receptor tyrosine kinase. Limited treatment options exist for aggressive systemic mastocytosis (ASM) and mast cell leukemia (MCL). We evaluated whether PKC412, a small-molecu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Gotlib, Jason, Berubé, Caroline, Growney, Joseph D., Chen, Ching-Cheng, George, Tracy I., Williams, Christopher, Kajiguchi, Tomohiro, Ruan, Jia, Lilleberg, Stan L., Durocher, Jeffrey A., Lichy, Jack H., Wang, Yanfeng, Cohen, Pamela S., Arber, Daniel A., Heinrich, Michael C., Neckers, Len, Galli, Stephen J., Gilliland, D. Gary, Coutré, Steven E.
Formato: Artigo
Idioma:Inglês
Publicado em: The American Society of Hematology 2005
Assuntos:
Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1895309/
https://ncbi.nlm.nih.gov/pubmed/15972446
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2005-04-1568
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados